Financial Performance - The company's revenue for Q3 2022 was CNY 159,406,578.99, a decrease of 4.45% compared to the same period last year, while year-to-date revenue increased by 39.32% to CNY 546,638,804.47[4] - The net profit attributable to shareholders for Q3 2022 was CNY -50,074.74, representing a decline of 100.44% year-on-year, while year-to-date net profit increased by 1.00% to CNY 18,821,966.80[4] - The company reported a 39.32% increase in year-to-date revenue, attributed to the growth in raw materials and intermediates business[8] - The company's revenue from sales of goods and services increased by 35.51% to CNY 493,216,569.03 compared to the same period last year[9] - Total operating revenue for the period reached CNY 546,638,804.47, an increase of 39.3% compared to CNY 392,370,845.33 in the previous period[19] - The net profit for Q3 2022 was CNY 24,700,043, an increase from CNY 19,059,198 in Q3 2021, representing a growth of approximately 29%[21] - Operating profit for Q3 2022 reached CNY 21,733,340, compared to CNY 12,749,034 in the same period last year, indicating a year-over-year increase of about 70%[21] - The total profit for Q3 2022 was CNY 21,168,292.62, an increase from CNY 12,393,017.36 in Q3 2021, reflecting a growth of approximately 71%[21] Cash Flow and Liquidity - The cash flow from operating activities showed a significant increase of 1,321.14% year-to-date, amounting to CNY 5,587,061.30[4] - Cash flow from operating activities generated a net amount of CNY 5,587,061, a significant increase from CNY 393,140 in Q3 2021[25] - The cash received from tax refunds surged by 3512.18% to CNY 15,464,851.54, mainly due to the receipt of tax refunds for retained taxes[9] - Cash flow from investment income increased by 59.57% to CNY 13,478,718.71, driven by higher returns from financial investments[9] - Investment activities generated a net cash flow of CNY 157,463,422, a turnaround from a negative cash flow of CNY -328,566,910 in the previous year[25] - The company’s cash and cash equivalents increased by 84.40% during the reporting period, reflecting improved liquidity[8] - The company reported a total cash and cash equivalents balance of CNY 339,383,162.56 at the end of Q3 2022, down from CNY 769,348,785.27 at the end of Q3 2021[25] Assets and Liabilities - The company's total assets at the end of Q3 2022 were CNY 2,675,416,767.73, a decrease of 0.82% from the end of the previous year[4] - Total assets decreased slightly to CNY 2,675,416,767.73 from CNY 2,697,511,886.43 at the start of the year, a decline of 0.8%[18] - The company's total current assets were CNY 1,432,881,677.64, down 9.4% from CNY 1,582,520,230.13 at the beginning of the year[17] - Total liabilities decreased to CNY 307,661,410.67 from CNY 354,456,572.37, a reduction of 13.2%[18] - The company's total equity rose to CNY 2,367,755,357.06 from CNY 2,343,055,314.06, an increase of 1.1%[18] Research and Development - The company’s R&D expenditure increased significantly by 1,631.37% to CNY 3,178,800.00, indicating a focus on new product development[8] - Research and development expenses increased to CNY 85,474,972.58, reflecting a rise of 17.2% from CNY 72,931,039.37 year-over-year[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,762, with the largest shareholder holding 32.76% of the shares[11] - The company plans to issue up to 36,631,249 shares through a simplified procedure to raise no more than CNY 300 million, which will not exceed 20% of the net assets from the previous year[14] Other Financial Metrics - The company's basic and diluted earnings per share for Q3 2022 were both CNY -0.0004, a decline of 100.37% year-on-year[4] - Investment income decreased by 47.12% to CNY 5,368,756.52, primarily due to the divestiture of subsidiaries in the previous reporting period[9] - The income tax expense decreased by 47.02% to CNY -3,531,750.38, reflecting the growth in profits during the reporting period[9] - The company’s financial expenses decreased to CNY -8,832,983.66 from CNY -9,133,424.13 in the previous year[21] - Basic and diluted earnings per share for Q3 2022 were both CNY 0.15, compared to CNY 0.18 in Q3 2021[22]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 387,232,225.48, representing a 71.69% increase compared to CNY 225,544,650.45 in the same period last year[22]. - The net profit attributable to shareholders was CNY 18,872,041.54, a significant increase of 161.49% from CNY 7,217,211.13 year-on-year[22]. - The net profit after deducting non-recurring gains and losses was CNY 8,138,113.45, up 145.50% from CNY 3,314,935.21 in the previous year[22]. - The basic earnings per share rose to CNY 0.15, an increase of 114.29% compared to CNY 0.07 in the same period last year[22]. - The total assets at the end of the reporting period were CNY 2,694,739,543.56, a slight decrease of 0.10% from CNY 2,697,511,886.43 at the end of the previous year[22]. - The net assets attributable to shareholders increased by 0.81% to CNY 2,343,272,685.80 from CNY 2,324,400,644.26 at the end of the previous year[22]. - The net cash flow from operating activities was negative at CNY -28,468,023.50, worsening by 228.35% compared to CNY -8,669,965.73 in the same period last year[22]. - The company reported a total non-operating income of 10,733,928.09, after accounting for tax effects and minority interests[27]. - The company received government subsidies amounting to 3,971,323.59, which are closely related to its normal business operations[26]. - The company reported a loss of 94,712.63 from the disposal of non-current assets, indicating challenges in asset management[26]. Research and Development - The company is actively involved in the research and development of innovative biopharmaceuticals, including a new drug for treating blood system tumors, which has completed Phase III clinical trials[31]. - The company has a leading product, Jinlujie (injection mouse nerve growth factor), which is the world's first commercialized nerve growth factor new drug, launched in 2003[34]. - The company’s innovative products include peptide immune modulators, which enhance the immune response against hepatitis B virus[37]. - The company’s core technology in 3CL protease inhibitors has entered the upstream supply chain for antiviral drugs, showcasing its R&D capabilities[38]. - The company is actively developing multiple small molecule generic drugs and raw materials, with significant progress reported in various projects, including the submission of new drug applications for several products[47]. - The company aims to increase the proportion of self-developed products through its own production capabilities[45]. - The company has established a strong R&D platform and is enhancing its independent R&D system, with a focus on optimizing talent structure and expanding research areas[49]. - The company has developed over 400 products, with 165 clinical approvals and 43 production approvals, including 26 new drug certificates, demonstrating its strong product pipeline[52]. - The company is in the NDA stage for its CPT project, a Class I anti-tumor new drug, indicating significant progress in its innovative drug development[52]. Market Strategy and Operations - The company plans to diversify its product offerings in the next three years, focusing on innovative biopharmaceuticals, small molecule CRO, CDMO, and high-end raw materials[47]. - The company’s subsidiary, Tianjin Hankan, provides comprehensive CRO services, including drug research and clinical trials, enhancing the value chain in pharmaceutical development[39]. - The company’s subsidiary, Xiamen Weijia, specializes in antiviral drug production and has become a key supplier of APIs and intermediates in the domestic and international markets[38]. - The company maintains strong channel advantages in neurology and oncology, supported by a nationwide sales service network and partnerships with major pharmaceutical distributors[53]. - The company is expanding its market presence by actively seeking overseas clients for its CRO and CDMO services, contributing to rapid business growth[47]. - The company emphasizes maintaining strong communication with regulatory experts to facilitate successful product registration[40]. - The company is focusing on enhancing its production capabilities through the establishment of a new manufacturing center for small-volume injectables and solid oral formulations[80]. - The company aims to improve operational efficiency and reduce reliance on single products through strategic acquisitions and investments in R&D[80]. Financial Management and Investments - The company reported a total of ¥519,399,287.66 in financial assets, with a fair value change of ¥1,800,064[68]. - The company has raised a total of 63,693.7 million CNY for various projects, with 41,612.1 million CNY actually invested, representing an investment progress of approximately 65.2%[80]. - The company has committed 6,590 million CNY to bank wealth management products and 18,000 million CNY to broker wealth management products, with no overdue amounts reported[82]. - The company has a total of 38,730 million CNY in entrusted wealth management, with all funds currently performing as expected[82]. - The company reported a net increase in cash and cash equivalents of ¥307,837,329.01, a 217.69% improvement compared to the previous year[57]. - The company reported a significant reduction in credit impairment losses, which were CNY -1,363,965.07 compared to CNY -11,447,012.70 in the first half of 2021[1]. - The company reported a net cash flow from investment activities of 342,258,067.83 CNY for the first half of 2022, a substantial improvement from -249,844,406.39 CNY in the same period of the previous year[178]. - The company reported a loan interest income of approximately CNY 2.97 million from Beijing Shadong Biotechnology Co., Ltd. during the first half of 2022[127]. Corporate Governance and Compliance - The company has established a robust corporate governance structure, ensuring compliance with relevant laws and regulations, and protecting the rights of all shareholders, especially minority shareholders[112]. - The company has implemented a comprehensive information disclosure management system to ensure timely and accurate communication with shareholders[113]. - The company has established a workers' representative assembly and union to safeguard employee rights and facilitate communication between employees and management[114]. - The company has not reported any significant litigation or arbitration matters during the reporting period, indicating a stable legal environment[124]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period, reflecting sound financial practices[120]. - The company has not engaged in any major related party transactions during the reporting period, maintaining transparency in its operations[125]. - The company has not encountered significant changes in the feasibility of its projects[76]. - The company has not undergone any bankruptcy restructuring or related matters during the reporting period, suggesting financial stability[123]. Environmental Responsibility - The company has a wastewater treatment capacity of 500 tons per day, with all wastewater treated to meet discharge standards[106]. - The company has implemented a self-monitoring plan for emissions, which has been approved by the environmental protection authority[109]. - There were no administrative penalties due to environmental issues during the reporting period[110]. - The company has established an emergency response plan for environmental incidents, which has been filed with the environmental protection department[108]. - The company emphasizes its commitment to social responsibility, engaging in charitable activities to support patients with neurological disorders and collaborating with environmental NGOs for sustainable development[116]. Shareholder Information - The largest shareholder, Wuhan Sanjiangyuan Investment Development Co., Ltd., holds 32.76% of the shares, totaling 40,000,000 shares[148]. - The second-largest shareholder, Chen Ya, holds 9.05% of the shares, totaling 11,050,000 shares, with 8,600,000 shares under lock-up[148]. - The company has a total of 12,689 shareholders at the end of the reporting period[148]. - The total number of unrestricted shares increased from 95,057,790 to 112,556,915, with an increase of 17,499,125 shares, representing 92.18% of the total[143]. - The company reported a total of 122,104,165 shares, with no changes in the number of shares during the reporting period[144]. - The report indicates that there were no new shares issued or repurchased during the period[146].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥387,232,225.48, representing a 71.69% increase compared to ¥225,544,650.45 in the same period last year[23]. - Net profit attributable to shareholders was ¥18,872,041.54, a significant increase of 161.49% from ¥7,217,211.13 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥8,138,113.45, up 145.50% from ¥3,314,935.21 year-on-year[23]. - The basic earnings per share increased to ¥0.15, reflecting a growth of 114.29% compared to ¥0.07 in the same period last year[23]. - The total revenue for the first half of 2022 was CNY 76,879,828.78, down from CNY 95,563,218.69 in the first half of 2021, indicating a decrease of about 19.6%[174]. - The company reported a net profit of 27,525,214.71 CNY from its subsidiary Tianjin Hankan Pharmaceutical Technology Co., Ltd., contributing significantly to overall performance[89]. - The total comprehensive income for the first half of 2022 was CNY 25,259,439.52, significantly higher than CNY 5,895,105.93 in the previous year[175]. - The company reported a net profit margin of 17.21%, indicating strong profitability in its operations[188]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,694,739,543.56, a slight decrease of 0.10% from ¥2,697,511,886.43 at the end of the previous year[23]. - The total liabilities stood at CNY 1,484,342,619.76, down from CNY 1,582,520,230.13, indicating a decrease of about 6.2%[162]. - The company's total assets as of June 30, 2022, were CNY 2,310,235,106.82, a decrease from CNY 2,408,921,477.70 at the beginning of the year[168]. - The company's equity attributable to shareholders was CNY 2,201,193,282.80 as of June 30, 2022, compared to CNY 2,212,159,233.74 at the beginning of the year, showing a slight decrease[168]. Cash Flow - The net cash flow from operating activities was negative at -¥28,468,023.50, worsening by 228.35% compared to -¥8,669,965.73 in the same period last year[23]. - The company reported a net cash outflow from operating activities of CNY -28,468,023.50, worsening from CNY -8,669,965.73 in the previous year[177]. - The cash and cash equivalents at the end of the period increased to 399,678,525.16 yuan from 139,956,757.84 yuan year-on-year, showing a substantial improvement in liquidity[181]. - The company reported a net increase in cash and cash equivalents of 325,969,246.27 yuan, contrasting with a decrease of -276,818,075.49 yuan in the same period last year, highlighting improved cash management[181]. Research and Development - The company is actively involved in the research and development of innovative drugs, with a focus on the Class I new drug CPT, which is currently in Phase III clinical trials and targets multiple types of malignancies[32]. - Research and development expenses rose by 41.45% to ¥60,503,393.53, reflecting increased investment in R&D projects[59]. - The company has a strong talent pool, with over 60% of its R&D team holding master's or doctoral degrees, enhancing its research capabilities[54]. - The company is focusing on innovation in biopharmaceuticals and small molecule CRO/CDMO sectors, with plans for multi-directional development over the next three years[49]. Market and Products - The company’s main products include the Class I new drug Jinlujie (injection mouse nerve growth factor) and the anti-hepatitis transfer factor, which are critical in the treatment of various neurological and viral diseases[35]. - The company’s subsidiary, Xiamen Weijia, specializes in the production of antiviral raw materials and intermediates, including Ritonavir and Lopinavir, and has been recognized as a key supplier in the national epidemic prevention efforts[39]. - The company has developed over 400 products, with 165 clinical approvals and 43 production approvals, showcasing its strong R&D output[54]. - The company plans to expand its market presence by launching new products in the second half of 2022, focusing on innovative biopharmaceutical solutions[187]. Governance and Compliance - The company has established a governance structure that includes a shareholders' meeting, board of directors, and supervisory board to enhance operational compliance and protect shareholder rights[112]. - The company has implemented a management system for information disclosure to ensure timely and accurate reporting to shareholders[113]. - The company has established a wastewater treatment facility with a capacity of 500 tons per day, ensuring compliance with environmental standards[106]. - The company has conducted environmental impact assessments for all construction projects as required[107]. Strategic Initiatives - The company is committed to expanding its market presence through strategic partnerships and technological advancements in drug development[32]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[187]. - The company has initiated the establishment of Guangzhou Huiying Pharmaceutical Technology Co., Ltd., which will be included in the consolidated financial statements[89]. Risks and Challenges - The company faces various risks including industry policy risks and new drug registration risks, which are detailed in the report[3]. - The company is facing risks related to industry policy changes that could impact pricing and market access for its products[90]. - The company has established a project management system for R&D to ensure new drugs align with market needs and to mitigate unpredictable risks[93].

武汉海特生物制药股份有限公司 2022 年第一季度报告全文 证券代码：300683 证券简称：海特生物 公告编号：2022-020 武汉海特生物制药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 166,204,766.30 | 157,828,324.48 | 5.31% | | 归属于上市公司股东的净利润（元） | 7,690,523 ...

Financial Performance - The company's operating revenue for 2021 was ¥614,683,452.35, representing a 17.28% increase compared to ¥524,123,427.37 in 2020[20]. - The net profit attributable to shareholders in 2021 was ¥27,654,228.04, a significant turnaround from a loss of ¥25,025,702.16 in 2020, marking a 210.50% increase[20]. - The net profit after deducting non-recurring gains and losses was ¥5,591,250.83 in 2021, compared to a loss of ¥42,196,910.19 in 2020, reflecting a 113.25% improvement[20]. - The company's total assets increased by 23.37% to ¥2,697,511,886.43 at the end of 2021, up from ¥2,186,566,003.25 at the end of 2020[20]. - The net assets attributable to shareholders rose by 36.04% to ¥2,324,400,644.26 at the end of 2021, compared to ¥1,708,652,006.75 at the end of 2020[20]. - The company reported a basic earnings per share of ¥0.260 in 2021, a significant increase from a loss of ¥0.240 per share in 2020, representing a 208.33% improvement[20]. - The weighted average return on equity was 1.52% in 2021, recovering from -1.44% in 2020[20]. - The company generated a net cash flow from operating activities of ¥12,088,247.37 in 2021, a 161.35% increase from a negative cash flow of ¥19,703,010.29 in 2020[20]. - Total revenue for 2021 reached ¥614,683,452.35, representing a year-on-year increase of 17.28% compared to ¥524,123,427.37 in 2020[63]. - Revenue from pharmaceutical technology services was ¥281,289,134.51, accounting for 45.76% of total revenue, with a year-on-year growth of 24.91%[63]. - The revenue from raw materials and intermediates surged by 3,174.77% to ¥102,258,145.15, significantly increasing its contribution to total revenue[63]. - Domestic sales accounted for 98.54% of total revenue at ¥605,726,002.55, with a year-on-year increase of 15.58%[63]. - Direct sales contributed ¥435,423,553.92, representing 70.84% of total revenue, with a growth of 23.72% compared to the previous year[63]. Market and Industry Outlook - The biopharmaceutical industry is projected to grow significantly, with the global market expected to reach $456.7 billion by 2024, reflecting a compound annual growth rate (CAGR) of approximately 9.8% from 2019[31]. - China's biopharmaceutical market is anticipated to grow to ¥712.5 billion by 2024, with a CAGR of about 18.0% from 2019[32]. - The global CRO market size increased from 44.3 billion USD in 2015 to 62.6 billion USD in 2019, and is expected to reach 96 billion USD by 2024, with a CAGR of approximately 8.9% from 2019 to 2024[35]. - The overall CRO industry in China is characterized by a fragmented market with low concentration, presenting significant growth opportunities due to increasing pharmaceutical R&D investments[36]. - The pharmaceutical market in China is projected to grow from RMB 1,633 billion in 2019 to RMB 2,228 billion by 2024, with a compound annual growth rate (CAGR) of approximately 6.42%[107]. Research and Development - The company has established six high-end formulation R&D platforms, significantly improving the success rate of drug project development[37]. - The company is actively developing multiple small molecule generic drugs and APIs, with ongoing projects progressing smoothly[51]. - The company has submitted a new drug application for the recombinant tumor necrosis factor project, awaiting approval from the National Medical Products Administration (NMPA)[51]. - The company has completed process validation for the recombinant human nerve growth factor eye drops project, transitioning from a lyophilized powder injection to an eye drop formulation[51]. - The company has submitted a generic drug application for parecoxib sodium injection, which is intended for short-term treatment of postoperative pain[51]. - The company has established a database of pharmaceutical experts to support its research and development efforts and ensure compliance with regulatory requirements[46]. - The company is focused on optimizing its talent structure and building research platforms to strengthen its independent R&D capabilities[51]. - The company has a strong talent pool with over 60% of its R&D team holding master's or doctoral degrees, and 90% of the core team members have extensive experience in project development[56]. - The company has invested 200 million RMB in new technology for drug development, aiming to improve production efficiency by 30%[145]. - The company plans to increase its R&D budget by 40% in 2022, focusing on innovative therapies[145]. Governance and Compliance - The company emphasizes the importance of accurate financial reporting and has declared the financial report to be true, accurate, and complete[4]. - The company has established a comprehensive governance structure to ensure compliance with relevant laws and regulations[124]. - The company has established a profit distribution policy, stating that cash dividends should not be less than 20% of the distributable profits for the year[125]. - The board of directors consists of 9 members, including 3 independent directors, in compliance with relevant regulations[126]. - The company has a complete and independent governance structure, ensuring independence in assets, personnel, finance, and operations from the controlling shareholder[129]. - The company has established a strict external guarantee system, with no guarantees provided for the controlling shareholder or its controlled enterprises[135]. - The company held three temporary shareholder meetings in 2021, with investor participation rates of 57.15%, 58.14%, and 50.42% respectively[136]. - The company has emphasized the importance of independent oversight in its governance practices, as evidenced by the appointment of new independent directors[140]. - The internal control self-assessment report indicates that there were no significant defects in internal controls during the reporting period[167]. - The internal control audit report confirmed that the company maintained effective internal controls related to financial reporting as of December 31, 2021[171]. Environmental Responsibility - HaiTe Biopharma reported a total chemical oxygen demand (COD) discharge of 0.713 tons per year, which is below the approved limit of 2.4 tons per year[174]. - The company has a wastewater treatment capacity of 500 tons per day, ensuring that all wastewater is treated to meet discharge standards[175]. - HaiTe Biopharma's ammonia nitrogen discharge is 0.039 tons per year, significantly lower than the approved limit of 0.45 tons per year[174]. - The company has established a comprehensive environmental management system and has a dedicated team for environmental protection[175]. - HaiTe Biopharma has implemented an emergency response plan for environmental incidents, which has been filed with the environmental protection department[177]. - The company has conducted regular drills to ensure effective response to potential environmental emergencies[177]. - HaiTe Biopharma has reported no administrative penalties related to environmental issues during the reporting period[179]. Strategic Initiatives - The company is focused on expanding its product pipeline in the fields of neurology and oncology, enhancing its market position[59]. - The company is constructing a new antiviral production facility, with the 103 antiviral workshop expected to be delivered within the year[115]. - The company is actively monitoring national pharmaceutical policies to mitigate risks associated with drug registration and market competition[116]. - The company aims to reduce reliance on single products through the acquisition of Hankan Pharmaceutical, enhancing its research and development capabilities[100]. - The company is in the process of acquiring a 6.9416% stake in Beijing Shadong Biological Technology Co., Ltd., indicating strategic expansion efforts[158]. - The company is also seeking to apply for a comprehensive credit facility from banks, which may enhance its financial flexibility[158]. Employee Engagement and Development - The total number of employees at the end of the reporting period was 1,143, with 268 in the parent company and 875 in major subsidiaries[160]. - The company employed 592 technical personnel, 336 production personnel, and 86 sales personnel, reflecting a strong focus on technical expertise[160]. - The educational background of employees included 11 with doctoral degrees, 186 with master's degrees, and 484 with bachelor's degrees, indicating a highly educated workforce[160]. - The company maintained a comprehensive salary system, ensuring timely payment of salaries, holiday bonuses, performance bonuses, and year-end bonuses despite the ongoing pandemic[161]. - In 2021, the company organized three training sessions focusing on various aspects of the pharmaceutical industry, enhancing employee knowledge and skills[162]. - The company conducted 8 Hiteck talk events to foster a culture of learning and sharing among employees, promoting engagement and collaboration[162]. Risks and Challenges - The company faces various risks including industry policy risks, new drug registration and market risks, and new drug development risks, which are detailed in the management discussion and analysis section[5]. - The report does not provide specific user data or performance guidance for the upcoming periods[5]. - There is no indication of market expansion or mergers and acquisitions in the current report[5]. - The CPT project is undergoing a Phase III clinical trial and is awaiting approval, with potential market risks if not included in the medical insurance directory[117]. - The high-end API production base project is significant, with potential risks related to market demand and policy changes affecting project viability[119].

证券代码：300683 证券简称：海特生物 公告编号：2021-062 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 武汉海特生物制药股份有限公司 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 2021 年第三季度报告 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末比上年 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 减 | 同期增减 | | | 营业收入（元） | 166,826,194.88 | 6.77% | 392,370,845.33 | 12.56% | | 归属于上市公司股东的 净利润（元） | ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥225,544,650.45, representing a 17.26% increase compared to ¥192,340,793.97 in the same period last year[21]. - The net profit attributable to shareholders was ¥7,217,211.13, a significant increase of 290.95% from a loss of ¥3,779,622.28 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥3,314,935.21, improving by 121.38% from a loss of ¥15,507,498.29[21]. - The basic earnings per share rose to ¥0.070, compared to a loss of ¥0.040 in the same period last year, marking a 275.00% increase[21]. - The total assets at the end of the reporting period were ¥1,932,685,294.96, down 11.61% from ¥2,186,566,003.25 at the end of the previous year[21]. - The net assets attributable to shareholders increased slightly by 0.45% to ¥1,716,278,584.38 from ¥1,708,652,006.75[21]. - The company reported a net cash flow from operating activities of -¥8,669,965.73, a decrease of 2.16% compared to -¥8,486,565.63 in the previous year[21]. - The weighted average return on net assets was 0.42%, an increase of 0.63% from -0.21% in the previous year[21]. - The company reported a total non-operating income of 3,902,275.92, with significant contributions from government subsidies amounting to 2,858,550.52 and gains from entrusted loans of 2,482,569.23[26]. - The company achieved significant growth in the biopharmaceutical sector, with the market size of China's biopharmaceutical industry projected to reach RMB 1,319.8 billion by 2030, maintaining a compound annual growth rate (CAGR) of 14.4% from 2018 to 2030[62]. - The company reported a rapid expansion in the domestic market for mouse nerve growth factor, with the market size growing from RMB 1.63 billion in 2013 to RMB 3.3 billion in 2016, reflecting an average CAGR of 26.5%[63]. Research and Development - The main business focuses on the research, production, and sales of innovative biopharmaceuticals, including the leading product, the injectable mouse nerve growth factor, which has been on the market since 2003[30]. - The company has established a protein structure simulation platform to enhance the success rate of recombinant protein construction and has developed impurity research and detection methods for its products[30]. - The company is actively developing new products, including injectable Parecoxib sodium and Esomeprazole sodium, with progress reported as smooth[30]. - The company is advancing the clinical research of its innovative drug CPT, which targets TRAIL death receptors and is in Phase III clinical trials for treating multiple myeloma[33]. - The company has received multiple national grants for its innovative drug development projects, including significant funding for the CPT project[33]. - The company emphasizes the importance of its core product, the injectable mouse nerve growth factor, which is widely used in various neurological injury repair applications[36]. - The company has developed a peptide immune regulator and enhancer drug, which is used for treating chronic hepatitis B patients, enhancing the immune response against the virus[37]. - The company has established a dedicated technology center that collaborates with institutions like Huazhong University of Science and Technology to drive new drug innovation[40]. - The company emphasizes continuous technical innovation and has established a talent and technology platform to enhance its R&D capabilities[41]. - The company has established four major research platforms for drug formulation, enhancing the success rate of drug development projects[65]. - The company has a strong talent pool with a high-quality management team and a rigorous adherence to GMP standards in drug production and quality management[70]. - The company is committed to enhancing its independent R&D system by optimizing talent structure and expanding R&D platforms[68]. - The company has established partnerships with prestigious universities to foster innovation and attract high-level talent for its R&D initiatives[73]. Market Strategy and Operations - The sales strategy includes participating in centralized procurement tenders across provinces, primarily selling through licensed distributors[49]. - The company offers comprehensive pharmaceutical research services, including project initiation, research scheme development, and regulatory submission support[53]. - The company has a comprehensive sales service network covering all provinces, cities, and counties in China, enhancing its market penetration in neurology and oncology[75]. - The company is focusing on expanding its product offerings in the neurology and oncology fields, with a pipeline that includes innovative and generic drugs[76]. - The company is transitioning Tianjin Hankan towards CDMO services, aiming to provide integrated R&D and production services for pharmaceutical companies[76]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[195]. Financial Management and Investments - The total amount of raised funds is RMB 797,475,854.40 after deducting various fees[96]. - The cumulative amount of raised funds utilized is RMB 56,590.97 million, with a change in purpose ratio of 67.52%[95]. - The investment in the biological engineering drug comprehensive formulation base upgrade project is RMB 22,000 million, with a completion rate of 100%[97]. - The investment in the R&D center and laboratory construction project is RMB 38,030 million, with a completion rate of 141.24%[97]. - The total investment in committed projects amounts to RMB 79,747.5 million, with a cumulative investment of RMB 25,905.4 million[97]. - The company has not achieved the planned progress for several projects, including the marketing service network upgrade project[97]. - The company has not encountered any issues with the use and disclosure of raised funds[104]. - The company has not engaged in derivative investments during the reporting period[104]. - The company has ongoing investments in construction projects, with capitalized costs increasing to CNY 135,388,452.79 from CNY 80,135,819.73, reflecting a growth of approximately 68.9%[186]. Environmental and Social Responsibility - The company has established a wastewater treatment facility with a capacity of 500 tons per day, ensuring that all wastewater is treated to meet discharge standards[128]. - The company reported a total emission of chemical oxygen demand (COD) at 1.81 tons per year, which is below the approved limit of 2.4 tons per year[128]. - The company has a dedicated environmental management team and strictly adheres to national and local environmental laws and standards[128]. - The company emphasizes social responsibility, aiming for a balance between economic and social benefits[133]. - The company has committed to supporting ecological protection and sustainable development through various charitable activities[137]. Corporate Governance and Compliance - The company has not experienced any significant litigation or arbitration matters during the reporting period[145]. - The company has not issued any non-standard audit reports for the previous year[144]. - There were no major related party transactions during the reporting period[148]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[149]. - The company has a receivable from a related party amounting to 13,050,000 yuan, with an interest rate of 3.85%[151]. - The company confirmed a non-taxable income of 2,482,569.23 yuan from a related party during the first half of 2021[151]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[132]. - The company has not sold any significant assets during the reporting period[107]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[124].

Financial Performance - The company reported a significant loss due to the removal of its main product, Nerve Growth Factor injection, from the national medical insurance catalog, leading to a decline in sales[5]. - The company's operating revenue for 2020 was ¥524,123,427.37, a decrease of 15.49% compared to ¥620,163,188.70 in 2019[25]. - The net profit attributable to shareholders in 2020 was -¥25,025,702.16, representing a decline of 139.70% from ¥63,035,065.41 in 2019[25]. - The net cash flow from operating activities was -¥19,703,010.29 in 2020, down 131.26% from ¥63,027,543.20 in 2019[25]. - The total income of 17,171,208.03 in the current period, a decrease from 27,950,105.56 in the previous year, representing a decline of approximately 38.5%[32]. - The company reported a quarterly operating revenue of ¥175,529,048.11 in Q4 2020, showing a sequential increase from previous quarters[28]. - The company incurred a net loss of -¥14,499,253.88 in Q4 2020, following losses in the previous quarters[28]. - The company has indicated uncertainty regarding its ability to continue as a going concern, as reflected in its financial performance[25]. Research and Development - R&D expenses increased by CNY 23.47 million compared to 2019, with R&D costs accounting for 16.43% of revenue, up from 10.10% in 2019[5]. - The company is developing a new drug, CPT, which has completed data lock and unblinding for its Phase III clinical trial, with results meeting expectations[9]. - The company plans to submit a New Drug Application (NDA) for CPT, pending regulatory review and approval processes[10]. - The company has a strong focus on R&D, with its main product "Jinlujie" being the world's first commercialized nerve growth factor new drug, launched in 2003[40]. - The company is advancing multiple projects, including the CPT project, which has completed Phase III clinical trials and is preparing for NDA submission[73]. - The CPT project has received significant funding and has multiple invention patents granted in 17 countries and regions[73]. - The company’s R&D services cover various therapeutic areas, including cardiovascular, respiratory, digestive, and endocrine systems[36]. - The company has established a comprehensive drug development service from R&D to clinical and production stages, enhancing its service offerings[36]. Market and Product Development - The company is focused on expanding its market presence with new products, particularly CPT, which could enhance its competitiveness if included in the medical insurance catalog[8]. - The company aims to increase the proportion of self-developed products through independent research and development of small molecule chemical drugs with good market prospects[58]. - The company is focusing on expanding its product offerings in the neurology and oncology fields, with a focus on innovative drug development[67]. - The company has established a comprehensive sales service network, collaborating with major distributors like Sinopharm and China Resources[67]. - The company has launched online promotional activities for its NGF product and conducted charitable drug donation campaigns to support patients during the pandemic[76]. Assets and Investments - The total assets at the end of 2020 were ¥2,186,566,003.25, an increase of 0.79% from ¥2,169,508,822.12 at the end of 2019[25]. - The net assets attributable to shareholders decreased by 2.49% to ¥1,708,652,006.75 at the end of 2020 from ¥1,752,293,190.99 at the end of 2019[25]. - The company's fixed assets increased by 28.27% compared to the previous year, amounting to ¥59,169,240.07, primarily due to construction projects and equipment purchases[63]. - Intangible assets grew by 48.92%, totaling ¥31,207,073.52, mainly from the increase in land use rights[63]. - The company has a total of RMB 479,569,950.00 in financial assets, with a fair value change of RMB 2,648,143.84[107]. Corporate Governance and Compliance - The company has not experienced any major litigation or arbitration matters during the reporting period[142]. - There were no significant penalties or rectification measures during the reporting period[143]. - The company has not engaged in any significant related party transactions during the reporting period[145]. - The company has established a dedicated bank account for managing the raised funds, ensuring proper oversight and usage[112]. - The company has committed a total investment of CNY 79,747.59 million, with a cumulative investment of CNY 42,599.49 million, achieving 53.41% of the planned investment[115]. Strategic Focus and Future Plans - The company is committed to becoming China's leading innovative drug enterprise, focusing on patient service and continuous innovation[127]. - The company plans to focus on the development of biopharmaceuticals, small molecule CRO, CDMO, and high-end raw materials in the future[124]. - The company aims to enhance operational efficiency and shareholder value through the acquisition of Hankan Pharmaceutical, which has a strong product line and R&D team[118]. - The company is in the process of issuing stocks to raise funds for the industrialization of its new drug CPT and the first phase of its raw material drug production base[77]. - The company has not proposed any cash dividend distribution plan for the reporting period despite having positive distributable profits[133].

2021-034 武汉海特生物制药股份有限公司 2021 年第一季度报告全文 武汉海特生物制药股份有限公司 2021 年第一季度报告 2021 年 04 月 1 武汉海特生物制药股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈亚、主管会计工作负责人夏汉珍及会计机构负责人(会计主管 人员)羡雯声明：保证季度报告中财务报表的真实、准确、完整。 2 武汉海特生物制药股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 157,828,324.48 | 64,692,430.52 | 143.97% | | 归属于上市公司股东的净利润（元） ...

武汉海特生物制药股份有限公司 2020 年第三季度报告全文 武汉海特生物制药股份有限公司 2020 年第三季度报告 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈亚、主管会计工作负责人夏汉珍及会计机构负责人(会计主管 人员)羡雯声明：保证季度报告中财务报表的真实、准确、完整。 2020-071 2020 年 10 月 1 武汉海特生物制药股份有限公司 2020 年第三季度报告全文 2 武汉海特生物制药股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,128,227,648.15 | 2,169,508,822.12 | | -1.90% | | 归属于上市公司股东的净资 ...